I

Instituto Medico Rio Cuarto | Research Center | Rio Cuarto, Argentina

Research site
(Unclaimed)
Location
Hipolito Irigoyen 1020, Rio Cuarto, Cordoba, Argentina
Site insights

Top conditions

COVID-19 (1 trial)

Lung Cancer (1 trial)

Non-Muscle Invasive Bladder Cancer (1 trial)

Infections (1 trial)

Respiratory Tract Infections (1 trial)

Top treatments

TAR-200
Rilematovir
Pembrolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

3 of 4
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Biological: BCG Vesiculture

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: M7824

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Nov...

Enrolling
Covid19
Biological: Placebo
Biological: Novaferon

Trial sponsors

Janssen logo

Janssen (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems